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Abstract
 Skeletal muscle is central to whole body metabolic homeostasis,Background:
with age and disease impairing its ability to function appropriately to maintain
health. Inadequate NAD  availability is proposed to contribute to
pathophysiology by impairing metabolic energy pathway use. Despite the
importance of NAD  as a vital redox cofactor in energy production pathways
being well-established, the wider impact of disrupted NAD  homeostasis on
these pathways is unknown.
 We utilised skeletal muscle myotube models to induce NADMethods:
depletion, repletion and excess and conducted metabolic tracing to provide
comprehensive and detailed analysis of the consequences of altered NAD
metabolism on central carbon metabolic pathways. We used stable isotope
tracers, [1,2-13C] D-glucose and [U- C] glutamine, and conducted combined
2D-1H,13C-heteronuclear single quantum coherence (HSQC) NMR
spectroscopy and GC-MS analysis.
 NAD  excess driven by nicotinamide riboside (NR) supplementationResults:
within skeletal muscle cells results in enhanced nicotinamide clearance, but
had no effect on energy homeostasis or central carbon metabolism.
Nicotinamide phosphoribosyltransferase (NAMPT) inhibition induced NAD
depletion and resulted in equilibration of metabolites upstream of
glyceraldehyde phosphate dehydrogenase (GAPDH). Aspartate production
through glycolysis and TCA cycle activity is increased in response to low NAD ,
which is rapidly reversed with repletion of the NAD  pool using NR. NAD
depletion reversibly inhibits cytosolic GAPDH activity, but retains mitochondrial
oxidative metabolism, suggesting differential effects of this treatment on
sub-cellular pyridine pools. When supplemented, NR efficiently reverses these
metabolic consequences. However, the functional relevance of increased
aspartate levels after NAD  depletion remains unclear, and requires further
investigation.
 These data highlight the need to consider carbon metabolismConclusions:
and clearance pathways when investigating NAD  precursor usage in models
+
1 1 1 1
1 1 1 2
2 1 1
1
2
   Referee Status:
  Invited Referees
 version 1
published
15 Nov 2018
 1 2
report report
, King's College London, UKPaul Caton1
, University ofJoseph A. Baur
Pennsylvania, USA
2
 15 Nov 2018,  :147 (First published: 3
)https://doi.org/10.12688/wellcomeopenres.14898.1
 15 Nov 2018,  :147 (Latest published: 3
)https://doi.org/10.12688/wellcomeopenres.14898.1
v1
+
+
+
+
+
13
+
+
+
+ +
+
+
Page 1 of 20
Wellcome Open Research 2018, 3:147 Last updated: 12 DEC 2018
  These data highlight the need to consider carbon metabolismConclusions:
and clearance pathways when investigating NAD  precursor usage in models
of skeletal muscle physiology.
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Introduction
Nicotinamide adenine dinucleotide (NAD+) is an essential 
cofactor responsible for driving oxidoreductase reactions 
throughout glycolysis, the tricarboxylic acid (TCA) cycle, and 
the electron transport chain (ETC)1,2. Maintaining NAD+/reduced 
NAD+ (NADH) redox homeostasis is important for effective 
ATP production, which is essential for metabolically active 
tissues to meet functional demand3. NAD+ has since also been 
recognised as a signalling molecule and is intracellularly 
consumed by enzymes such as sirtuins, poly-ADP-ribose 
polymerases (PARPs) and cADP-ribose synthases (CD38s). 
In order to maintain normal cellular function, it is critical for 
NAD+ to be replenished through either biosynthetic or salvage 
pathways4–6.
Pathological changes to skeletal muscle have consequences on 
whole body energy metabolism as seen in disease states such 
as obesity, diabetes and sarcopenia7–9. A reduction in NAD+ 
levels of between 30 and 85% have been reported in the 
muscle tissue of aged mice with an associated impairment in 
mitochondrial function5,10–14. Reduced NAD+ availability may 
also be a molecular mechanism involved in the aetiology of 
muscle dysfunction in more common metabolic diseases, 
including obesity and type II diabetes10–12. Augmentation 
of muscle NAD+ levels through precursor supplementation 
(i.e. nicotinamide riboside (NR), nicotinamide mononucleotide 
(NMN)) may be a means to improve metabolic capacity and 
function in a range of age-related disease states15. NR and NMN 
are often supplemented in large doses and can lead to increased 
cellular NAD+ content. Chronically increasing NAD+ beyond 
normal physiological levels could have a wider impact on 
metabolic homeostasis, which is yet to be fully understood.
The role of NAD+ in accepting electrons from glycolytic and 
TCA cycle metabolites enables oxidative phosphorylation and 
highlights the NAD+/NADH redox couple as being vital to 
central carbon metabolism. Based on the decline in NAD+ 
observed in chronic disease we studied the impact this may 
have on energy homeostasis. In light of the recent work 
showing NR can safely elevate NAD+ metabolism in human 
blood16, alongside the increasing focus on NAD+ precursors as a 
treatment strategy for metabolic diseases, we sought to explore 
the metabolic impact of altered NAD+ levels in the context of 
skeletal muscle16–18.
Here we established scenarios of NAD+ excess and depletion, 
previously modelled in other studies12,19,20, and aimed to more 
intensively define the consequences of disrupted NAD+ on 
essential metabolic pathways in skeletal muscle, providing 
advances to the current work in the field. We initially employed 
1D-1H-NMR, which has higher resolution and reproducibility 
than other quantification methods, such as GCMS21. Further to 
this, we utilised metabolic tracing to understand the impact of 
altered NAD+ levels on carbon metabolism. The stable isotope 
tracer [1,2-13C] D-glucose was used to generate metabolite label-
ling patterns and visualised through advanced 2D-1H,13C- het-
eronuclear single quantum coherence (HSQC) nuclear magnetic 
resonance (NMR) spectroscopy and gas chromatography–mass 
spectrometry (GC-MS) analysis22. This methodology allowed 
for in-depth analysis of glucose-derived carbon molecules, 
with the ability to determine information regarding spe-
cific metabolic pathways within different compartments23. 
Detailed analysis of lactate and alanine are key to underpin-
ning changes to glycolysis and the pentose phosphate pathway 
(PPP) within the cytosol. Investigation of glutamate and 
aspartate, using this method, can determine whether synthesis 
has occurred from pyruvate entering the mitochondria via 
pyruvate dehydrogenase or pyruvate carboxylase22,23. Further 
to this, information regarding the number of rounds of the TCA 
cycle can be determined, which once again can be used to 
understand changes to the activity of the TCA cycle in response 
to differing NAD+ states.
Here we present detailed evidence of adaptations to pathway 
utilisation within central carbon metabolism in response to 
low NAD+ levels in skeletal muscle, which are reversible with 
short-term NR supplementation.
Methods
Unless otherwise stated all materials and reagents were acquired 
from Sigma-Aldrich, UK
Culture of the murine C2C12 muscle cell line
C2C12 myoblasts were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM) 25 mM glucose supplemented with 10% 
foetal bovine serum (FBS) and 1% Penicillin/Streptomycin 
(P/S). Once cells reached 70% confluence, differentiation 
medium was added (DMEM 25 mM glucose supplemented with 
5% horse serum (HS) and 1% P/S) and the cells were cultured 
for 5 days with fresh medium added every other day, sufficient to 
differentiate myoblasts into mature contractile myotubes.
Primary myotube culture
Experiments were conducted consistent with current UK 
Home Office regulations in accordance with the UK Animals 
(Scientific Procedures) Act 1986, and approved by the local 
Animal Welfare and Ethical Review Body. Gastrocnemius 
muscle was collected from 16-week-old male C57BL/6NJ mice 
and placed in 0.2% collagenase, to allow for myofibre detach-
ment and digestion and then washed in DMEM. Myofibres 
were placed in wells coated with Matrigel (BD biosciences), 
with DMEM containing 30% FBS, 10% HS, 1% chick embryo 
extract (CEE), 1% P/S and 0.1% fibroblast growth factor (FGF). 
Following satellite cell migration the media was replaced with 
proliferation media; DMEM supplemented with 10% HS, 0.5% 
CEE and 1% P/S. Once cells had attained 70–80% confluence 
the media was replaced with differentiation media (DMEM 
supplemented with 2% HS, 0.5% CEE and 1% P/S) and left to 
differentiate for 6 days, as previously described24.
Cell treatments
Cells were either left as control or treated with 50 nM FK866 for 
24 or 48 hours and then co-treated with 0.5 mM NR (Chromadex, 
California) for 4 hours.
13C-glucose and 13C-glutamine labelling
Cells (2x106) were seeded into 15 cm dishes and differentiated 
for 5 days. For glucose labelling, freshly made flux media 
(DMEM powder (without glucose, L-glutamine, phenol red, sodium 
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pyruvate or sodium bicarbonate), diluted in 1 litre of distilled 
water, supplemented with 2 mM glutamine and 45 mM sodium 
bicarbonate) was added to the cells 24 hours prior to extraction; 
10 mM 13C2-[1,2]-D-Glucose was then added and the cells 
were left to metabolise. For glutamine labelling the media was 
alternatively supplemented with 10 mM glucose, 45 mM sodium 
bicarbonate and 2 mM 13C5-glutamine.
Extraction of metabolites from cells
Media was aspirated and plates were placed on dry ice to 
quench metabolism prior to extraction of metabolites from the 
cells. Cells were washed with ice-cold 0.9% saline solution and 
1.2 ml HPLC-grade methanol (-80°C) was added to the plate. 
The cells were transferred to a falcon tube where 1.2 ml of 
HPLC-grade chloroform (-20°C) was added. The tube was 
rocked at 4°C for 10 minutes before 1.2 ml pre-chilled HPLC- 
grade H2O was added and left to rest on ice for 10 minutes. 
Separation of the polar and non-polar fractions was achieved 
through centrifugation at 4°C, 14,200 rpm for 15 minutes. Next, 
2 ml of the polar fraction was stored for NMR analysis, with 
200 µl removed for GC-MS. Both fractions were evaporated 
to dryness using a SpeedVac at 30°C for 4–5 hours and stored 
at -80°C until further analysis. Protein pellet weights were used 
for normalisation during analysis; extractions were conducted 
on at least three different experiments.
NMR spectroscopy
Dried NMR samples were re-suspended in 100 mM sodium 
phosphate buffer containing 500 µM 4,4-dimethyl-4-silapentant-1-
sulfonic acid (DSS) and 10% deuterium (D2O), pH 7.0. Samples 
were sonicated and transferred to glass vials before being moved 
to 1.7 mm NMR tubes using a Gilson robotic system.
A Bruker Avance III 600 MHz NMR spectrometer equipped 
with a 1.7 mm z-PFG TCI Cryoprobe was used to acquire 2D 
1H,13C-HSQC NMR spectra. The HSQC spectra were acquired 
with echo/anti-echo gradient coherence selection with an 
additional pre-saturation for suppressing the water resonance. 
The spectral widths were 13.018 ppm and 160.0544 ppm in the 
direct and indirect dimension, 512 complex data points were 
acquired for the 1H dimension and 29.9927% (2457) out of 
8192 complex data points were acquired for the 13C indirect 
dimension using a non-uniform sampling scheme. The interscan 
relaxation delay was set to 1.5 s. 2D 1H,13C-HSQC spectra 
were reconstructed via the compressed sensing algorithm 
using the MDDNMR (version 2.5) and NMRPipe (version 9.2) 
software25–27. All spectra were processed without baseline 
correction as this can present challenges for the multiplet 
analysis procedure.
A total of 128 transients were acquired for each 1D-1H NMR 
spectrum with a relaxation delay of 4 s. Each sample underwent 
automatic tuning and matching before they were shimmed 
(1D-TopShimm) to a DSS line width of <1 Hz prior to acquisition 
of the first spectrum. Total experiment time was 4 h 45 min per 
sample; ~15 min for 1D-1H-NMR and 4.5 h for 2D-1H,13C-HSQC 
NMR spectra. All 1D-1H NMR spectra were processed using 
MetaboLab software (version 1). Data analysis was performed 
using MetaboLab with the methyl group of lactate used to 
calibrate the chemical shift28. Prior to Fourier Transformation all 
1D-1H-NMR spectra were zero-filled to 131,072 data points, the 
chemical shift was then calibrated by referencing the DSS signal 
to 0 ppm and the spectra were manually phase-corrected. Once 
complete, the baseline correction was conducted using a spline 
function (ref: 61) and the spectra were exported into Bruker 
format to allow for metabolite identification and quantifica-
tion using the Chenomx software package (ChenomxINC, 
version 7.0). All metabolite concentrations were normalised to 
pellet weight.
GC-MS
Polar metabolites were solubilised in 2% methoxyamine 
hydrochloric acid (HCL) in pyridine. The samples were 
vortexed before being incubated at 60°C for 60 minutes. 
Following this incubation the derivatisation reagent was added; 
60 µl N-tertbutyldimethylsilyl-N-methyltrifluoroacetamide 
(MTBSTFA) with 1% (w/v) tertbutyldimethyl-chlorosilane 
(TBDMSCI) (Sigma-Aldrich). The suspension was incubated 
for 1 h at 60°C in a closed tube to prevent evaporation. The 
samples were centrifuged at 13,000 rpm for 5 min and the 
clear supernatant was transferred to a chromatography vial with a 
glass insert (Thermo Fisher). Derivatised samples were analysed 
using an Agilent 7890B Series GC/MSD gas chromatograph 
with a medium polar range polydimethylsiloxane GC column 
(DB35-MS), in association with a mass spectrometer (GC-MS) 
(Agilent Technologies). Metabolite ion counts were normalised to 
pellet weight.
Glycogen assay
Glycogen was extracted from differentiated C2C12s and 
quantified using a Glycogen Assay Kit (Sigma-Aldrich) according 
to the manufacturer’s instructions.
Respirometry
C2C12s were differentiated for 5 days and treated with 50 nM 
FK866 for 48 or 72 h. Mitochondrial function was then 
determined using a two-chamber Oxygraph (OROBOROS 
Instruments) derived from polarographic oxygen flux measure-
ments. Prior to loading into the chambers cells were removed 
from the plates by Trypsin and spun down to form a pellet before 
being suspended in 2 ml DMEM. Once within the chambers 
the cells were left to incubate for 10 min to measure their 
endogenous respiration. Following this 10 µg/2 ml of digitonin 
was added to permeabilise the cells. Assessment of oxidation 
capacity was carried out by sequentially subjecting the cells to 
differing concentrations of substrate as follows; 2 mM malate 
and 10 mM glutamate as a substrate for complex I and determi-
nation of complex I respiratory capacity, 5 mM increments of 
ADP until maximal oxidative phosphorylation and induction of 
state III respiration, 10 µM cytochrome c as a control for 
mitochondrial membrane damage, 20 mM succinate as a substrate 
for complex II and assessment of complex I + II respiratory 
capacity, 0.5 mM carbonyl cyanide-4-(trifluoromethoxy) 
phenylhydrazone (FCCP) titrations until maximal respiration 
increase to determine maximal uncoupled respiratory capacity, 
0.5 µM rotenone for inhibition of complex I and assessment of 
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complex II maximal respiratory capacity, and 2.5 µM antimycin 
A for inhibition of complex III to determine residual oxygen 
consumption. Following experiment chamber contents were 
collected, spun down, washed in PBS and a Bradford assay 
was conducted to calculate protein levels within each sample. 
These were then used to determine oxygen flux/mg of protein. 
Respiratory substrate stocks were diluted in ddH2O, while 
uncouplers and inhibitors were diluted in absolute ethanol.
LCMS
Prepared samples were analysed on a LCMS platform 
consisting of an Accela 600 LC system and an Exactive mass 
spectrometer (Thermo Scientific). A Sequant ZIC-pHILIC 
column (4.6 mm × 150 mm, 5 µm) (Merck) was used to sepa-
rate the metabolites with the mobile phase mixed by A= 20 mM 
ammonium carbonate in water and B= acetonitrile. A gradient 
program starting at 20% of A and linearly increasing to 80% at 
30 min was used followed by washing (92% of A for 5 min) and 
re-equilibration (20% of A for 10 min) steps. The total run time 
of the method was 45 min. The LC stream was desolvated and 
ionised in the HESI probe. The Exactive mass spectrometer was 
operated in full scan mode over a mass range of 70–1,200 m/z 
at a resolution of 50,000 with polarity switching. The LCMS 
raw data was converted into mzML files by using ProteoWizard 
(v3.0.4472, 64-bit) and imported to MZMine (2.10) for peak 
extraction and sample alignment. A house-made database 
including all possible 13C isotopic m/z values of the relevant 
metabolites was used for the assignment of LCMS signals. Finally 
the peak areas were used for comparative quantification.
Statistical analysis
All statistical analyses were carried out using the GraphPad 
Prism 6 software. One-way ANOVA analysis has been conducted 
on the concentrations of metabolites and percentages of label 
incorporation, with Dunnett’s multiple comparisons post hoc 
test. This was to test differences between the treatment groups 
with statistical significance shown by * p<0.05, ** p<0.01, *** 
p<0.001, compared to control.
Results
NAD+ excess does not impact pathway use in central 
carbon metabolism
NR and NMN supplementation as a strategy to increase or 
recover NAD+ availability has been extensively used in models 
of pathophysiology associated with NAD+ deficiency and 
impaired metabolism11. The wider metabolic consequences of 
increasing cellular NAD+ above physiological levels have yet to 
be established. Therefore, we first examined the consequences 
of NAD+ excess on metabolic pathway use and energetic status 
in muscle cells. Using 1D-1H-NMR spectroscopy we 
quantified changes to key metabolites involved in NAD+ metab-
olism following 0.5 mM NR or NMN supplementation in 
control cells. As expected, 4-hour NR and NMN were effec-
tive at significantly elevating intracellular NAD+ levels in C2C12 
cells, with a similar significant increase seen in primary 
myotubes following NR supplementation (Figure 1B, C). There 
was no effect of NR or NMN supplementation on NADP+ in 
either C2C12s or primary myotubes (Figure 1D, E). NAM, the 
breakdown product and precursor of NAD+, was significantly 
elevated in cells treated with NR and NMN. NR had a greater 
effect on NAM with a 9-fold increase above control compared 
to NMN (1.8-fold) (Figure 1F, G). NAM clearance was also 
elevated, with methylated NAM (MeNAM) levels significantly 
increased with NR but not NMN supplementation in C2C12s 
(Figure 1H). Interestingly, there was no change in MeNAM 
after NR supplementation in primary myotubes despite a large 
increase in NAM (Figure 1I). We used the phosphocreatine/ 
creatine (PCr/Cr) ratio, to show there was no change in ATP 
demand as a result of NAD+ excess following supplementa-
tion with either precursor in C2C12s or primary myotubes 
(Figure 1J, K).
To further characterise the effect of NAD+ excess on carbon 
metabolism we used [1,2-13C] D-glucose and conducted 
combined analysis of GC-MS and 2D-1H,13C-HSQC spectra to 
elucidate changes to metabolic pathway utilisation (Figure 1L). 
The use of [1,2-13C] D-glucose as an isotopic tracer delivers 
distinct labelling patterns based on whether the PPP has been 
utilised, which we may expect to change with varying NAD+ 
levels. Lactate was used as a measure of glycolytic and PPP 
activity, with no change observed in concentration or pathway 
utilisation with NR or NMN (Figure 1L–N). In order to identify 
TCA cycle changes aspartate was used as a surrogate; once 
again, no change in concentration or pathway use was observed 
(Figure 1O–R). To investigate whether a longer supplementa-
tion of NR would induce changes to carbon metabolism we 
conducted a 24-hour NR study. Similar to the 4-hour supple-
mentation period, both NAM and MeNAM levels were elevated 
suggesting increased clearance of NAD+ metabolites (Supple-
mentary Figure 1C, D) but carbon metabolism was unchanged 
(Supplementary Figure 1G–H).
These data show that both acute and chronic NAD+ excess 
within a skeletal muscle cell results in increased NAM clear-
ance but has no immediate effect on energy homeostasis or 
central carbon metabolism based on the endpoints measured. We 
proceeded to use the 4-hour NR supplementation for our NAD+ 
rescue experiments to show the acute effects of NAD+ repletion 
using NR.
NR supplementation can rescue NAD+ depletion and 
reverse FK866 induced energy stress
We next created a model of NAD+ depletion in muscle cells to 
assess the consequences for central carbon metabolism. The 
NAMPT inhibitor FK866 was used to deplete NAD+, and NR as a 
means to rescue (Figure 2A). We used 1D-1H-NMR spectroscopy 
to confirm that the cell models were effective at altering NAD+ 
levels and quantify key NAD+-related metabolites. Treatment 
of both fully differentiated C2C12 and primary myotubes with 
50 nM FK866 for 48-hours resulted in a 95% reduction in 
NAD+, which was rescued to above normal levels with 4-hour 
0.5 mM NR supplementation (Figure 2B). NADP+ levels were 
also significantly supressed by FK866 and restored with NR 
(Figure 2C), consistent with previous data20. NAM levels were 
unchanged with FK866 treatment but increased with the addi-
tion of NR (Figure 2D). Despite basal MeNAM concentrations 
Page 5 of 20
Wellcome Open Research 2018, 3:147 Last updated: 12 DEC 2018
Figure 1. NAD+ excess has no consequence on pathway use within central carbon metabolism. Differentiated C2C12 and primary 
myotubes were treated with NR or NMN (0.5 mM) for 4 hours, pathway shown in (A). Key metabolites were identified and quantified using 
1D-1H-NMR spectroscopy and used to inform on the energetic status of the cell; (B, C) NAD+, (D, E) NADP+. Fold-change compared to 
control were shown for (F, G) nicotinamide (NAM) and (H–I) methylated-nicotinamide (MeNAM); red line is representative of control levels. 
(J, K) The phosphocreatine (PCr)/creatine (Cr) ratio. (L) Resulting labelling patterns of glucose flux through metabolic pathways. Concentration 
and labelling patterns detected through combined analysis of 2D-1H,13C-NMR (13C1,2-glucose) and GC-MS data of (M–O) lactate and 
(P–R) aspartate. 13C represented by 1 with 12C represented by 0; % MID of total metabolite. All concentrations in mM. * p<0.05, ** p<0.01, 
***p<0.005; One-way ANOVA performed on raw data; Dunnett’s multiple comparison test, treatment compared to control. All data are the 
mean ±SEM, C2C12s n=6. Primary myotubes n=4. FC, fold change compared to control; MID, mass isotopomer distribution.
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Figure 2. NAMPT inhibition induces energetic stress in skeletal muscle. Differentiated C2C12 and primary myotubes were treated with 
FK866 (50 nM) for 48 hours with and without NR (0.5 mM) for 4 hours, pathway shown in (A). Key metabolites were identified and quantified 
using 1D-1H-NMR spectroscopy and used to inform on the energetic status of the cell; (B) NAD+, (C) NADP+, (D) nicotinamide (NAM), 
(E) methylated-nicotinamide (MeNAM), (F) combined ATP and ADP and (G) the phosphocreatine (PCr)/ creatine (Cr) ratio. (H) Lactate/
Pyruavte ratio from GC-MS analysis using the m=2 portion of the MID. (I) High resolution respirometry was carried out on differentiated 
C2C12s treated with 50 nM FK866 for 24, 48 or 72 hours. * p<0.05, ** p<0.01, ***p<0.005; One-way ANOVA performed on raw data; Dunnett’s 
multiple comparison test, treatment compared to control. All data are the mean ±SEM, C2C12s n=6. Primary myotubes n=4.
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being higher in primary myotubes compared to C2C12s the 
levels remained unchanged throughout the different treatment 
groups (Figure 2E). Additional metabolites of interest were 
measured by 1D-1H-NMR (Table 1). There was no significant 
change detected in either lactate or alanine production through 
glycolysis following NAD+ depletion (Supplementary Figure 2).
Although there was no change in overall ATP and ADP levels 
across the groups in either C2C12 or primary myotubes, the 
decrease in the PCr/Cr ratio shown in the FK866 samples is 
evidence the cells are buffering ATP availability in the face of 
metabolic stress induced by NAD+ depletion (Figure 2F, G). 
Also suggestive of altered cytosolic redox is an increase in the 
lactate/pyruvate ratio, though this was only present in C2C12s 
(Figure 2H). To further understand whether the change to the 
PCr/Cr ratio and redox potential with NAD+ depletion impacted 
energy metabolism, high-resolution mitochondrial respirom-
etery was conducted and showed lowered maximal respiration 
following 72-hour FK866 treatment (Figure 2F).
Together these data show that NAD+ depletion by inhibition of 
NAMPT alters the energy status of the cell through changes to 
the PCr/Cr ratio, which can be rescued through short-term NR 
supplementation, via the NRK enzymes. The unchanged lactate 
and alanine data is equally interesting as it highlights how 
adaptable skeletal muscle cells are at coping with severely 
depleted NAD+ levels.
NAD+ depletion causes reversal of glycolytic reactions at 
NAD+ dependent GAPDH
To understand how changes to energy metabolism pathways 
within the muscle cell affect metabolite levels, GC-MS ion 
count analysis was conducted on both C2C12s and primary 
myotubes. A significant increase in metabolites glyceraldehyde-3- 
phosphate (G3P) (Figure 3A) and glycerol-3-phosphate 
(Figure 3B), upstream of GAPDH were detected in 48-hour 
FK866 treated C2C12 and primary myotubes compared to 
untreated control myotubes. This effect was not observed in the 
24-hour FK866-treated cells. Corroborating previous studies, this 
data is suggestive of an NAD+-dependent reduction in activity of 
GAPDH, occurring between 24- and 48-hour NAD+ depletion19,20. 
NR rescue in FK866-treated C2C12s was able to release the 
block evidenced by a reduction of GAP to control levels. This was 
not shown in the primary myotubes, with G3P levels remaining 
above control following NR supplementation. Presence of a block 
after 48-hour FK866 treatment was further supported by signifi-
cantly reduced levels of downstream TCA cycle metabolites cit-
rate, a-ketoglutarate (a-KG), and malate in C2C12s and primary 
myotubes (Figure 3C–H). NR rescue was effective at returning all 
metabolites to control levels in both models. The data is summa-
rised as a schematic in Figure 3I. A number of other metabolites 
were identified through GC-MS ion count analysis (Table 2).
We hypothesised that the accumulation of G3P would result 
in a shift in equilibrium and therefore reversal of glycolytic 
reactions. In order to study this, we measured fructose-6- 
phosphate using 2D-1H-13C-HSQC NMR spectroscopy. We noted 
Table 1. Cellular metabolite concentrations from 1D-NMR 
spectra. Metabolite concentrations taken from 1D-NMR spectra 
analysed through Chenomx software.
Metabolite
Cellular Metabolite Concentrations 
(mM/mg of protein)
Control FK866 FK866 NR
Mean SEM Mean SEM Mean SEM
1,3-Dimethylurate 0.00 0.03 0.00 0.01 0.00 0.01
1,7-Dimethylxanthine 0.00 0.00 0.00 0.00 0.00 0.05
2-Aminoadipate 0.01 0.01 0.01 0.01 0.01 0.01
2-Aminobutyrate 0.06 0.08 0.06 0.08 0.07 0.07
2-Hydroxyisobutyrate 0.00 0.00 0.00 0.00 0.00 0.01
2-Hydroxyisocaproate 0.02 0.08 0.04 0.06 0.03 0.05
2-Oxoisocaproate 0.00 0.02 0.00 0.01 0.00 0.01
3-Hydroxyisovalerate 0.00 0.00 0.00 0.00 0.00 0.00
3-Methyl-2-oxovalerate 0.01 0.01 0.01 0.01 0.01 0.01
Acetoacetate 0.01 0.01 0.01 0.02 0.01 0.01
Alanine 0.07 0.12 0.08 0.10 0.09 0.15
Arabinose 0.03 0.05 0.04 0.22 0.04 0.04
Asparagine 0.00 0.01 0.00 0.01 0.01 0.01
Choline 0.01 0.02 0.01 0.01 0.01 0.02
Citrate 0.01 0.02 0.01 0.02 0.02 0.02
Dimethylamine 0.00 0.00 0.00 0.01 0.00 0.00
Fumarate 0.00 0.00 0.00 0.00 0.00 0.00
Galactarate 0.01 0.03 0.02 0.03 0.01 0.03
Glucose 0.00 0.01 0.14 0.01 0.01 0.09
Glutathione 0.05 0.06 0.05 0.06 0.06 0.06
Glycine 0.08 0.18 0.11* 0.21 0.15 0.20
Hydroxyacetone 0.01 0.02 0.01 0.02 0.02 0.02
Imidazole 0.00 0.02 0.01 0.00 0.00 0.01
Nicotinamide N-oxide 0.00 0.00 0.00 0.00 0.00 0.00
O-Acetylcarnitine 0.00 0.01 0.00 0.01 0.00 0.01
O-Acetylcholine 0.01 0.02 0.01 0.02 0.01 0.01
Phenylalanine 0.04 0.12 0.05 0.10 0.03 0.09
Pyruvate 0.01 0.01 0.01 0.02 0.01 0.02
Succinate 0.00 0.01 0.01 0.01 0.01 0.01
Taurine 0.26 0.45 0.29* 0.47 0.22 0.51
Threonine 0.07 0.09 0.09* 0.24 0.07 0.09
Tryptophan 0.01 0.02 0.01 0.01 0.01 0.02
Tyrosine 0.05 0.16 0.08 0.14 0.04 0.12
Valine 0.06 0.20 0.10 0.18 0.06 0.16
*p<0.05; Two-way ANOVA performed on all data; Dunnett’s multiple 
comparison test. n=6.
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Figure 3. Block in glycolysis at GAPDH following NAD+ depletion. Data shown are fold changes of ion counts from GCMS compared to 
control in both NAD+ deplete (FK866; 48 h) and replete (FK866; 48 h + NR; 4 h) cells, showing (A) glyceraldehyde-3-phosphate, (B) glycerol-
3-phosphate, (C, D) citrate, (E, F) a-ketoglutarate, (G, H) malate. (I) A diagrammatic representation of glycolysis and the TCA cycle in C2C12 
and primary myotubes treated with FK866 for 48 h. An increase in ion count compared to control shown in peach and a decrease shown in 
blue. * p<0.05, ** p<0.01, ***p<0.005; One-way ANOVA performed on raw data; Dunnett’s multiple comparison test, treatment compared to 
control. All data are the mean ±SEM, n=4.
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Table 2. Cellular metabolite ion counts from GCMS. Ion counts taken from GCMS. No significant 
changes seen between conditions.
Metabolite Cellular metabolite ion counts
Control FK866 24h FK866 48 h FK866 48 h, NR 4h
Mean SEM Mean SEM Mean SEM Mean SEM
Tryptophan 49720 57190 64405 55845 53202 52914 55327 47893
Serine 415367 164737 237489 187173 845253 783737 686931 1055501
Pyruvate 255065 168133 146860 97016 124497 13889 358317 191197
Proline 163717 121858 231244 177360 174065 207804 15691 11678
Malate 147186 112783 114083 89299 73951 64911 142479 159432
Lactate 8345878 7825695 8367333 5174489 7446052 5382583 8998869 3275040
Histidine 646757 551284 741234 488925 706205 654021 605624 362069
Glycine 9116697 7104045 8635419 6465350 7972076 7955743 8503790 6814356
G3P 1174906 826308 1530734 1046045 2273705 2037600 1700887 1223394
Glutamine 942572 1003918 1448528 791723 1545368 1797213 898866 858392
Fumarate 81303 67667 90462 60750 91008 76830 95761 69124
Cysteine 203170 263833 356747 119714 369724 210067 311876 86770
Alanine 1541322 730418 967774 739846 1398345 1367006 1349550 1382444
3-PG 11227 11048 15149 6286 22499 33977 16770 11633
*** p<0.005; Two-way ANOVA performed on all data; Dunnett’s multiple comparison test. n=4.
elevated 13C-label incorporation in carbon 1 of 48-hour FK866 
samples compared to both control and 24-hour FK866 samples. 
This was interesting but could be anticipated as a result of 
glycolysis using [1,2-13C] D-glucose (Figure 4A). Investigation 
of the label incorporation into carbon 5 of fructose-6-phopshate 
also highlighted 48-hour FK866 samples as showing a differ-
ential labelling pattern compared to 24-hour FK866 and control 
samples (Figure 4B). The only metabolic route to incorporate 
label into carbon 5 of fructose-6-phosphate is through reversed 
glycolytic reactions, which we suggest to be the result of an 
NAD+-dependent block at GAPDH (Figure 4C). This hypothesis 
is further supported through LCMS analysis of FK866 samples 
traced with [U-13C] D-glucose. A significant increase in the 
m+6 portion of fructose-1,6-bisphosphate is shown with 48-hour 
FK866 treatment which is normalised with the addition of NR 
(Figure 4D). Again, this suggests NAD+ depletion can cause 
a build-up of metabolites above GAPDH and a reversal of 
glycolytic reactions. We postulated that this may constitute 
glycogenesis and therefore result in elevated glycogen levels 
within the FK866 samples, however glycogen storage appeared 
to be unaffected (Figure 4E).
NAD+ depletion leads to elevated mitochondrial derived 
aspartate
Following the reduced ion count shown of key TCA metabolites, 
as a result of the GAPDH block in FK866 samples, we were 
surprised to find a significantly elevated aspartate concentra-
tion in both C2C12 and primary myotubes (Figure 5A, B). 
Combined analysis of the 2D-1H-13C-HSQC spectra and GC-MS 
data showed significant alterations to pathway utilisation for 
aspartate, evidenced by differential labelling patterns occurring 
after FK866 treatment, which were reversed with an acute dose 
of NR (Figure 5C, D). The absolute amount of aspartate pro-
duced from each pathway is presented in Figure 5E, F, which not 
only shows increased aspartate production through glycolysis 
and the TCA cycle, but also an elevated unlabelled proportion 
of the metabolite. Generation of unlabelled aspartate is evidence 
of a non-glucose carbon source being used; in the absence of 
NAD+ we postulated that the cell may favour glutamine use 
over NAD+ dependent glycolysis. To investigate this, we used 
[U-13C] glutamine as a nutrient. Label incorporation into 
aspartate from glutamine was significantly elevated in FK866 
samples, but only in the 2-only labelled and 3-only labelled 
portion (Figure 5H). The metabolic route to these labelling 
patterns is shown in Figure 5G, and depicts increased glutamine 
use is only evident following multiple TCA cycle rounds. This 
shows that the cells do not use glutamine as a regular source of 
carbon for aspartate production under normal conditions, and 
only begin to do this in response to FK866 treatment.
We postulated that the build-up of aspartate may be a result 
of impaired malate-aspartate shuttle (MAS) functioning as a 
result of perturbed cytosolic redox potential, as evidenced by 
the elevated lactate/pyruvate ratio. We tested this hypothesis 
using a MAS inhibitor in combination with [1,2-13C] D-glucose. 
We were successful in increasing the lactate/pyruvate ratio 
(Supplementary Figure 3A) and as a result increased NADH 
oxidation for this reaction in the cytosol. We decreased pyruvate 
entering the mitochondria, resulting in depleted TCA metabo-
lite levels (Supplementary Figure 3B, C) and significantly less 
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Figure 4. Investigation of reversed glycolytic reactions. Fructose-6-phosphate was used to investigate reversal of glycolytic reactions as it 
appears before the block at GAPDH. Representative 2D-1H,13C-HSQC spectra were used to show 13C label incorporation in both control and 
FK866. (A) Carbon 1 shows peaks, therefore 13C label, in both 48-hour FK866 samples; (B) carbon 5 shows peaks in the FK866 samples, 
with no presence of 13C label in control or 24-hour FK866 samples. (C) Labelling pattern analysis shows how 13C1,2-glucose is metabolised 
to 1,2-labelled fructose-6-phosphate during glycolysis, explaining the label incorporation in carbon 1 in both control and FK866 samples. 
The route to 13C label in carbon 5 of fructose-6-phosphate is via 1,2-labelled glyceraldehyde-3-phosphate taking the backward reaction to 
fructose-1,6-bisphosphate. The presence of label incorporation in carbon 5 of FK866 samples is evidence of reversal of these reactions as 
a result of an NAD+-dependent build-up of G3P. (D) Glycogen levels of C2C12s. (E) m+6 portion of fructose-1,6-bisphosphate as shown 
through LCMS analysis. * p<0.05, One-way ANOVA performed on raw data; Dunnett’s multiple comparison test, treatment compared to 
control. All data are the mean ±SEM, n=3.
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Figure 5. Pathway utilisation for aspartate production is significantly altered with NAD+ depletion. Differentiated C2C12 and primary 
myotubes were treated with FK866 (50 nM) for 48 hours with and without NR (0.5 mM) for 4 hours. Aspartate concentration in both (A) C2C12s 
and (B) primary myotubes from 1D-NMR spectra. (C, D) Combined analysis of 2D-1H,13C-NMR (13C1,2-glucose) and GC-MS data provides 
labelling patterns for aspartate; (E, F) labelling patterns allow analysis of pathway utilisation for aspartate production. (G) Labelling patterns 
observed through 13C6-glutamine tracing. (H) Aspartate MIDs from combined 2D-1H,13C-NMR (13C5-glutamine) and GC-MS. Glycolysis 
1100+0011; TCA rounds + PPP 0100+0010, 1111, 0111+1110, 1000+0001; PC Activity 0110. * p<0.05, ** p<0.01, ***p<0.005; One-way 
ANOVA performed on raw data; Dunnett’s multiple comparison test, treatment compared to control. All data are the mean ±SEM, n=4.
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glucose label incorporation into glutamate (Supplementary 
Figure 3F). However, the effect on aspartate did not follow 
what we had previously seen with NAD+ depletion, with no 
increased levels and less label incorporation as opposed to more 
(Supplementary Figure 3D, E). NR was able to elevate NAD+ 
levels but had no other effect on the MAS inhibitor treated cells 
(Supplementary Figure 3G). Aspartate production following 
NAD+ depletion may serve as a muscle adaptive response, 
reversible with NR.
Discussion
Observation of elevated cellular NAD+ content in response to 
exercise29,30 and calorie restriction31 as a metabolic switch sig-
nalling augmented energy harvesting in muscle has prompted a 
focus on ways to increase NAD+ availability for treatment of 
metabolic disease in humans. Despite measurements linking a 
decline in NAD+ levels to altered metabolism, there is limited 
data showing the impact that NAD+ depletion, and also excess, 
could have on core cellular metabolism in muscle10–12.
Supplementation of NAD+ precursors in untreated cells results 
in an ‘NAD+-boost’ above control levels. The methodology 
employed in this study is key to understanding changes to meta-
bolic pathway usage. It was therefore surprising to discover 
that there was no alteration to the PPP activity or glycolysis in 
response to elevated NAD+. It became apparent that skeletal 
muscle cells rapidly adapt to an ‘NAD+-boost’ by increasing 
NAD+ clearance through NAM and MeNAM to protect the 
careful redox balance, seemingly to ensure central carbon 
metabolism is unaffected32.
A better understanding of the potential consequences of 
increased NAM and MeNAM clearance following NAD+ excess 
is important. Increased clearance will lead to increased levels 
circulating in the blood and ultimately elevated excretion in the 
urine, with previous studies suggesting high levels may exhibit 
adverse effects33–35. These metabolites are able to cross the blood-
brain barrier where there is strong evidence that they exhibit 
neuroprotection36–38. However, at high concentrations NAM 
and MeNAM can have a toxic effect on neurons, as shown in 
Parkinson’s and Huntington’s disease models39–41. Similarly, 
NAM has been shown to be effective for management of 
hyperphosphatemia in patients with renal disease42; however, it 
is also suggested to be a uremic toxin contributing to thrombo-
cytopenia43,44. Whilst there have been studies showing NR safely 
elevates NAD+ in human blood16,17,45 it is important to consider 
that creating a state of NAD+ excess and increasing clearance 
of NAM and MeNAM could potentially have unintended effects 
in the CNS and for kidney function.
Supplementation with NR and NMN in pre-clinical animal 
studies has shown similar therapeutic effects in disease conditions 
to preserve metabolic health and ameliorate age-related decline15. 
This prompted us to utilise both of these supplements to create an 
NAD+ excess and understand the impact they have on a skeletal 
muscle cell. These data show a difference between the NAD+ 
precursors, with a greater elevation of the clearance products, 
NAM and MeNAM, in NR compared to NMN treated cells. 
In order for mammalian cells to take up NMN and utilise it for 
NAD+ synthesis, it must first be converted to NR, which could 
account for the apparent decreased clearance rate compared 
to NR24,46. This is consistent with recent work conducted in 
mice showing that skeletal muscle metabolises NR faster than 
NMN47. An alternative explanation for the elevated NAM 
detected with NR may be due to its relative instability compared 
to NMN in culture medium, meaning it is possible that we are 
measuring NAM taken up by cells from the media due to NR 
degradation as opposed to intracellular NAD+ consumption46.
NAMPT inhibition significantly depletes NAD+, confirming this 
as the main pathway for basal NAD+ synthesis within skeletal 
muscle12. NAM levels are carefully balanced between con-
sumption, through NAD+ synthesis, and production, through 
NAD+ breakdown. NR rescue of FK866 treated cells causes an 
increase in NAM, suggestive of increased NAD+ breakdown, 
with NAMPT inhibition preventing NAM being used for NAD+ 
synthesis, therefore causing an accumulation. However, this 
build-up did not result in increased clearance through MeNAM 
possibly due to a delay in establishing NAD+ and NAM excess 
as FK866 treated cells must recover basal NAD+ levels first.
Evidence of disrupted energy homeostasis was seen with the 
reduction of the PCr/Cr ratio in NAD+-depleted cells. The hydroly-
sis of phosphocreatine and the resultant release of a phosphate 
group provides an alternative route to ATP production, avoiding 
carbohydrate metabolism and oxidative phosphorylation, which 
are both NAD+ dependent48,49. However, the levels of PCr are 
finite and therefore the cell cannot rely on this method of ATP 
synthesis indefinitely33. Importantly, supplementation with NR 
was sufficient to normalise NAD+ levels and prevented 
requirement for alternative ATP synthesis.
A significant effect of NAD+ depletion is inhibition of GAPDH, 
the first NAD+-dependent step of glycolysis. The build-up of 
metabolites before the enzyme, coupled with the decrease 
in metabolites observed downstream in response to NAMPT 
inhibition corroborates previous studies in cancer cells and 
C2C12s12,19. The advanced analysis conducted through the 
combined NMR and GCMS methodology allowed us to confirm 
the reversal of the glycolytic reactions above the block, not just 
through steady-state metabolite levels, but also through label 
incorporation into fructose-6-phosphate. This highlighted that 
although changes to metabolite concentrations were observed 
after 24-hour FK866 treatment, the inhibition of cytosolic 
GAPDH, and reversal of glycolytic reactions, is not detected until 
the 48-hour time-point.
Aspartate is a partner in a number of cellular metabolic energy 
cycles. Previous work using a malate-aspartate shuttle inhibitor 
in vascular smooth muscle yielded similar results to our FK866 
treatment of an increase in glucose-derived aspartate34. A key 
limitation of the experiment may be the mechanism of action of 
the inhibitor, given it indirectly inhibits the shuttle functioning 
by acting on cytosolic aspartate aminotransferase35. This there-
fore does not confirm whether a different aspect of the shuttle 
may be impaired in our model, but does show that the results are 
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unlikely to be a result of compromised cytosolic aspartate 
aminotransferase activity. Aspartate is also a key component in 
the purine nucleotide cycle, which is active in skeletal muscle in 
response to energy depletion, removing AMP to promote ATP 
synthesis and could provide an alternative use for the aspartate 
build-up50. Elevated aspartate has also been reported in cells 
treated with the mitochondrial uncoupler FCCP51, supporting the 
notion that the effects are a result of perturbed cytosolic redox. 
Elevated GAP and G3P observed with NAMPT inhibition may 
represent an attempt to maintain the redox potential within the 
cytosol, by utilising the glycerol-3-phosphate/dihydroxyacetone 
phosphate shuttle to regenerate NAD+ and provide protons to the 
electron transport chain52.
Aspartate could be a marker of a preserved mitochondrial 
NAD+ pool allowing for continued TCA cycle activity despite 
cytosolic NAD+ depletion. This is supported by our data indicat-
ing mitochondrial respiration still occurs despite severe NAD+ 
depletion. NAD+/NADH ratios differ greatly between subcellular 
compartments, with mitochondrial redox more tightly regu-
lated compared to the cytosol53,54. The notion of a protected 
mitochondrial NAD+ pool is suggested in other studies, which 
have indicated that FK866 treatment affects cytosolic NAD+ but 
does not disrupt the mitochondrial NAD+ pool12,20,55. Together this 
suggests that skeletal muscle is able to resist disruptions to 
mitochondrial metabolism and maintain oxidative function 
despite severe NAD+ depletion.
The methods employed in this study provide a high-resolution 
insight into metabolism and changes to metabolic pathways. 
Detailed analysis of energy metabolism pathways, as conducted 
here, could be key to understanding disease pathophysiology 
and may uncover novel cellular adaptations, which are not seen 
using other methods.
In conclusion, these data show NR is acutely effective at 
reversing changes to central carbon metabolism observed 
following severe NAD+ depletion. NR and NMN in skeletal 
muscle cells does not impact carbon metabolism but does 
increase clearance products of NAD+, which may impact other 
tissues in whole body metabolism. We observed a change in 
aspartate production with regard to both concentration and 
route to production. Understanding whether this is a cellular 
adaptation to low NAD+ or if there is a functional use of the 
aspartate requires further investigation and could provide insight 
into how our skeletal muscle copes with energy stress.
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Supplementary material
Supplementary Figure 1. Chronic NR supplementation.
1D-1H-NMR spectroscopy shows (A) NAD+ and (B) NADP+ concentrations in C2C12s in response to 24-hour NR supplementation. 
Fold-change compared to control shown for (C) NAM and (D) MeNAM. Energetic status of the cell was investigated through (E) ATP and 
(F) PCr/Cr ratio. Combined analysis of 2D-1H,13C-NMR (13C1,2-glucose) and GC-MS data of (G) lactate and (H) aspartate. One-way 
ANOVA performed on raw data; Dunnett’s multiple comparison test, treatment compared to control. All data are the mean ±SEM, C2C12s 
n=4.
Click here to access the data
Supplementary Figure 2. Glycolytic outputs, lactate and alanine, unaffected by NAD+ depletion.
Differentiated C2C12 and primary myotubes were treated with FK866 (50 nM) for 48 hours with and without NR (0.5 mM) for 4 hours. 
1D-1H-NMR spectroscopy shows (A) Lactate concentration in C2C12 and primary myotubes (mM/mg of protein). Combined 2D-1H-13C-
NMR and GC-MS analysis shows pathway contribution to lactate in (B) C2C12 and (C) primary myotubes. Alanine concentration (mM/mg 
of protein) in (D) C2C12s and (E) primary myotubes with alanine pathway analysis in (F) C2C12 and (G) primary myotubes. One-way 
ANOVA performed on all data, with individual pathways assessed independently; Dunnett’s multiple comparison test, treatment compared 
to control. All data are the mean ±SEM, n=4.
Click here to access the data
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Supplementary Figure 3. MAS Inhibitor does not have same effect as FK866 treatment.
Differentiated C2C12s were treated with 0.5 mM AOAA (MAS Inhibitor) for 24 hours with or without 0.5 mM NR for 4 hours. (A) Lac-
tate/Pyruvate ratio from GC-MS analysis using the m=2 portion of the MID. GCMS ion count fold changes compared to control for (B) 
a-KG, (C) succinate and (D) aspartate. MIDs from GCMS analysis for (E) aspartate and (F) glutamate. 1D-1H-NMR spectroscopy shows 
(G) NAD+ concentration (mM/mg of protein). MAS – Malate aspartate shuttle. * p<0.05, ** p<0.01, ***p<0.005; One-way ANOVA per-
formed on all data, with individual MIDs assessed independently; Dunnett’s multiple comparison test, treatment compared to control. All 
data are the mean ±SEM, n=3.
Click here to access the data
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NAD just as much without causing the same degree of NAM accumulation. This could be easily
addressed by monitoring the culture media.
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Figure 1D shows NADP+ is not increased by 4 hours of NR as described in the text, but Figure
S1B shows the opposite result
O2 flux in Figure 2 has no units
Absolute NAD concentration shown in Figure 2 is much lower than expected
It would be useful to show NAD depletion at 24 hours of FK866 to help understand why it takes 48
hours to see a major block in GAPDH
I’m not sure why Figure 3A shows GAP and 3B shows G3P when the rest of the panels show the
same metabolite for each cell type. It would be easier to compare if both were shown for both cell
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metabolism during NAD excess and depletion. The use of multiple state-of-the-art techniques has
uncovered several novel effects of NAD excess and depletion which will be important when considering
the utility of NAD boosting compounds as potential therapies for various pathophysiological conditions. 
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